Insomnia - Drug Pipeline Landscape, 2023

Insomnia - Drug Pipeline Landscape, 2023

Insomnia is a sleep disorder that is characterized by difficulty falling asleep or staying asleep. Insomnia can be caused by a variety of factors, including stress, anxiety, depression, medications, and medical conditions. Treatment for insomnia typically includes lifestyle changes, such as avoiding caffeine and establishing a regular sleep schedule, as well as cognitive behavioral therapy and, in some cases, medication.

There are two types of insomnia primary and secondary. Primary insomnia is characterized by sleep problems that aren't linked to any other health condition or problem. Secondary insomnia is trouble sleeping because of a health condition like, depression, arthritis, cancer, pain or substance use.

Insomnia causes include stress, travel or work schedule, poor sleep habits. Other causes include medications, mental health disorders, sleep related disorders, medical conditions, caffeine, nicotine and alcohol.

Symptoms of insomnia include daytime fatigue or sleepiness. irritability, depression, or anxiety, poor concentration and focus, a lack of coordination, leading to errors or accidents, worry or anxiety about sleeping

Diagnosis of Insomnia involves physical exam, sleep habits review and sleep study.

Treatment options of Insomnia include counselling, cognitive behavioral therapy, or CB, prescription medications and over-the-counter sleep aids.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Insomnia treatment such as CLM-IN01, Daridorexant, YZJ-1139, and others. Key players involved in the development of therapies to treat Insomnia are Closed Loop Medicine Ltd, Idorsia Pharmaceuticals, Janssen Research & Development and others. Two drugs are under Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

In Oct 2022, Idorsia Pharmaceuticals announced top-line positive results of Japanese Phase III clinical study.

Report Highlights

Global Insight Service's, Insomnia - Drug Pipeline Landscape, 2023 report provides an overview of the Insomnia pipeline drugs. This report covers detailed insights on Insomnia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Insomnia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Insomnia - Pipeline Drugs, 2023-Coverage
2. Disease Overview - Insomnia
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Insomnia - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Late Stage Drugs-Pre-Registration
5.1.1 Daridorexant
5.1.2 CLM-IN01
5.2 Clinical Stage Drugs-Phase III
5.2.1 EVT 201
5.2.2 Lemborexant
5.2.3 Seltorexant
5.2.4 SM-1
5.2.5 YZJ-1139
5.3 Clinical Stage Drugs-Phase II
5.3.1 CANabidiol
5.3.2 CB2810
5.3.3 Defined CBD
5.3.4 TS-142
5.3.5 V117957
5.3.6 Zolpidem
5.4 Clinical Stage Drugs-Phase I
5.4.1 HEC83518
5.5 Early Stage Drugs-Discovery
5.5.1 CBIS-SD-001
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Bod Australia
9.2 Cannabis Science Inc
9.3 Cennerv Pharma (S) Pte Ltd
9.4 Closed Loop Medicine Ltd
9.5 Defined Research
9.6 Eisai Co., Ltd
9.7 EMS
9.8 Evotec International GmbH
9.9 Idorsia Pharmaceuticals Ltd.
9.10 Imbrium Therapeutics
9.11 Janssen Research & Development, LLC
9.12 Sequential Medicine Ltd
9.13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
9.14 Sunshine Lake Pharma Co., Ltd.
9.15 Taisho Pharmaceutical Co., Ltd.
11. Appendix
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – EVT 201/Evotec International GmbH
Table 2.2 Clinical Trial Details – Lemborexant/Eisai Co., Ltd
Table 2.3 Clinical Trial Details – Seltorexant/Janssen Research & Development, LLC
Table 2.4 Clinical Trial Details – SM-1/Sequential Medicine Ltd
Table 2.5 Clinical Trial Details – YZJ-1139/Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Table 2.6 Clinical Trial Details – CANabidiol /Bod Australia
Table 2.7 Clinical Trial Details – Defined CBD/Defined Research
Table 2.8 Clinical Trial Details – TS-142/Taisho Pharmaceutical Co., Ltd.
Table 2.9 Clinical Trial Details - SVT-4A1011/Servatus Limited
Table 2.10 Clinical Trial Details – V117957/Imbrium Therapeutics
Table 2.11 Clinical Trial Details – Zolpidem/EMS
Table 2.12 Clinical Trial Details – HEC83518/Sunshine Lake Pharma Co., Ltd.
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Insomnia, 2023
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Insomnia, 2023
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Insomnia, 2023
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Insomnia, 2023
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Insomnia, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings